Leukocyte perturbation associated with Fabry disease

Journal of Inherited Metabolic Disease

Volumn 32, Issue SUPPL. 1, 2009, Pages

  Rozenfeld, P ^a   Agriello, E ^b   De Francesco, N ^a   Martinez, P ^b   Fossati, C ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Hospital Penna   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA GALACTOSIDASE A, HUMAN; ALPHA-GALACTOSIDASE A, HUMAN; CERAMIDE TRIHEXOSIDE; GLOBOTRIAOSYLCERAMIDE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; ENZYME REPLACEMENT; FABRY DISEASE; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; CASE-CONTROL STUDIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; TRIHEXOSYLCERAMIDES; YOUNG ADULT;

EID: 84880992758     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1060-9     Document Type: Article

References (36)

1. Arias Martinez N, Barbado Hernandez FJ, Perez Martin G, et al (2003) Fabry's disease associated with rheumatoid arthritis. Multisystemic crossroads. An Med Interna 20: 28-30.
2. Askari H, Kaneski CR, Semino-Mora C, et al (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 451: 823-834. doi:10.1007/s00428-007-0468-6. (Pubitemid 47497940)
3. Balreira A, Lacerda L, Miranda CS, et al (2005) Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. Br J Haematol 129: 667-676. doi:10.1111/j.1365-2141.2005.05503.x. (Pubitemid 40825829)
4. Beck M (2006) The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 95: 43-46. doi:10.1080/08035320600618825.
5. Brady RO, Gal AE, Bradley RM, et al (1967) Enzymatic defect in Fabry disease. N Engl J Med 276: 1163-1167.
6. Bruck W, Goebel HH, Dienes P (1991) B and T lymphocytes are affected in lysosomal disorders - an immunoelectron microscopic study. Neuropathol Appl Neurobiol 17: 219-222. doi:10.1111/j.1365-2990.1991.tb00717.x.
7. Burstein Y, Zakuth V, Rechavi G, et al (1987) Abnormalities of cellular immunity and natural killer cells in Gaucher's disease. J Clin Lab Immunol 23: 149-151.
8. Cabrita M, Pereira C, Rodrigues P, et al (2005) Altered expresión of CD1d molecules and lipid accumulation in the human hematoma cell line HepG2 after iron loading. FEBS J 272: 152-165. doi:10.1111/j.1432-1033.2004.04387.x. (Pubitemid 40083075)
9. Costello R, O'Callaghan T, Sebahoun G (2006) Gaucher disease and multiple myeloma. Leuk Lymphoma 47: 1365-1368. doi:10.1080/10428190600565453. (Pubitemid 44269647)
10. Deegan PB, Baehner AF, Barba Romero MA, et al (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43: 347-352. doi:10.1136/jmg.2005.036327.
11. DeGraba T, Azhar S, Dignat-George F, et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47: 229-233. doi:10.1002/1531-8249(200002)47:2〈229::AID-ANA13〉3.0.CO;2-T. (Pubitemid 30078570)
12. Dellabona P, Padovan E, Casorati G, et al (1994). An invariant a24-JaQ/Vb11 T cell receptor is expressed in all individualls by clonally expanded CD4-CD8- T cells. J Exp Med 180: 1171-1176. doi:10.1084/jem.180.3.1171.
13. Dobrovolny R, Dvorakova L, Ledvinova J, et al (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population. J Mol Med 83: 647-654. doi:10.1007/s00109-005-0656-2. (Pubitemid 41176074)
14. Fox H, McCarthy P, André-Schwartz J (1984) Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and B-cell proliferations? Cancer 54: 312-314. doi: 10.1002/1097- 0142(19840715)54:2〈312::AID-CNCR2820540222〉3.0.CO;2-I. (Pubitemid 14076615)
15. Gadola SD, Silk JD, Jeans A, et al (2006) Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med 203: 2293-2303. doi:10.1084/jem.20060921. (Pubitemid 44498364)
16. Hamers MN, Donker-Koopman WE, Coulon-Morelec MJ, et al (1978) Characterization of antibodies and globoside. Immunochemistry 15: 353-358. doi:10.1016/0161-5890(78)90130-X.
17. Kieseier BC, Goebel HH (1994) Characterization of T-cell subpopulations and NK-cells in lysosomal disorders by immuno-electron microscopy. Neuropathol App Neurobiol 20: 604-608. doi:10.1111/j.1365-2990.1994.tb01015.x.
18. Kieseier BC, Wisniewiski KE, Goebel HH (1997) The monocyte-machrophage system is affected in lysosomal storage diseases: an immunoelectron microscopic study. Acta Neuropathol 94: 359-362. doi:10.1007/s004010050719. (Pubitemid 27450116)
19. Kint JA (1970) Fabry disease. Alpha galactosidase deficiency. Science 167: 1268-1269. doi:10.1126/science.167.3922.1268.
20. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 38: 750-760. doi:10.1136/jmg.38.11.750. (Pubitemid 33032930)
21. Marie JP, Tulliez M, Tricottet-Paczinski V, et al (1982) Gaucher's disease with monoclonal gammopathy. Significance of splenic plasmacytosis. Scand J Haematol 28: 54-58. (Pubitemid 12180442)
22. Marti GE, Ryan ET, Papadopoulos NM, et al (1988) Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 29: 189-194. doi:10.1002/ajh.2830290403. (Pubitemid 19004117)
23. Martinez P, Aggio M, Rozenfeld P (2007) High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis 30: 365-369. doi:10.1007/s10545- 007-0513-2. (Pubitemid 46881683)
24. Micheva I, Marinakis T, Repa C (2006) Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cells Mol Dis 36: 298-307. doi:10.1016/j.bcmd.2005.12.029.
25. Rahman P, Gladman DD, Wither J, et al (1998) Coexistence of Fabry's disease and systemic lupus erythematosus. Clin Exp Rheumatol 16: 475-478. (Pubitemid 28370863)
26. Ries M, Gupta S, Moore DF, et al (2005) Pediatric Fabry disease. Pediatrics 115: e344-355. doi:10.1542/peds.2004-1678. (Pubitemid 43373019)
27. Rosenmann E, Kobrin I, Cohen T (1983) Kidney involvement in systemic lupus erythematosus and Fabry's disease. Nephron 34: 180-184. doi:10.1159/000183006. (Pubitemid 13096580)
28. Rozenfeld PA, Croxatto O, Ebner R, et al (2006) Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients. Clin Exp Ophthalmol 34: 689-694. doi:10.1111/j.1442-9071.2006. 01318.x. (Pubitemid 44363621)
29. Schumann J, Facciotti F, Panza L, et al (2007) Differential alteration of lipid antigenpresentation to NKT cells due to imbalances in lipid metabolism. Eur J Immunol 37: 1431-1441. doi:10.1002/eji.200737160. (Pubitemid 46939480)
30. Shen JS, Meng XL, Moore DF, et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95: 163-168. doi:10.1016/j.ymgme. 2008.06.016.
31. Simonaro CM, Haskins ME, Schuchman EH (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the muchpolysaccharidoses. Lab Invest 81: 1319-1328. doi:10.1038/labinvest.3780345. (Pubitemid 32911980)
32. Spada FM, Koezuka Y, Porcelli SA (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188: 1529-1534. doi:10.1084/jem.188.8.1529. (Pubitemid 28489590)
33. Sugita M, Cernadas M, Brenner MB (2004) New insights into pathways for CD1-mediated antigen presentation. Curr Opin Immunol 16: 90-95. doi:10.1016/j.coi.2003.11.014. (Pubitemid 38198122)
34. Whybra C, Schwarting A, Kriegsmann J, et al (2006) IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol 21: 1251-1256. doi:10.1007/s00467-006-0176-5. (Pubitemid 44203450)
35. Wu YP, Mizukami H, Matsuda J, et al (2005) Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol Genet Metab 84: 9-17. doi:10.1016/j.ymgme.2004.08.017. (Pubitemid 40082600)
36. Zhou D, Mattner J, Cantu III C, et al (2004) Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789. doi:10.1126/science.1103440. (Pubitemid 39601398)